Coherus Oncology (CHRS) Short term Debt (2014 - 2023)

Coherus Oncology (CHRS) posted Short term Debt of $3.3 million for Q4 2023, down 18.32% sequentially from $4.0 million in Q3 2023.

Coherus Oncology (CHRS) Short term Debt (2014 - 2023) Analysis & Trends

Coherus Oncology has reported Short term Debt for 6 years, with the latest figure at $3.3 million in Q4 2023.

Quarterly Short term Debt changed N/A year-over-year to $3.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.3 million (changed N/A YoY) and the FY2023 annual result came in at $3.3 million, changed N/A from the prior year.
Short term Debt declined to $3.3 million in Q4 2023 per CHRS's latest filing, from $4.0 million in the prior quarter.
Over five years, Short term Debt peaked at $17.3 million in Q3 2021 and troughed at $3.3 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.90 Bn	132.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn
3	Argenx Se	65.73 Bn	60.55 Bn	1.37 Bn
4	Moderna	58.33 Bn	53.19 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.72 Bn	28.42 Bn	992.69 Mn
7	BioNTech SE	28.27 Bn	9.88 Bn	668.28 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn
9	Royalty Pharma	27.25 Bn	26.41 Bn	-
10	Coherus Oncology	213.65 Mn	108.34 Mn	10.07 Mn

Download Data